Vancomycin for Enterococcus Infections
Ampicillin or amoxicillin 2 g IV every 4 hours is the first-line treatment for non-VRE Enterococcus infections, with vancomycin reserved as an alternative agent for penicillin-allergic patients or when ampicillin resistance is documented. 1
When Vancomycin is Indicated
Vancomycin should be used for Enterococcus infections in these specific scenarios:
- Penicillin allergy: When ampicillin/amoxicillin cannot be used 1
- Ampicillin-resistant strains: Documented resistance to beta-lactams 2
- Vancomycin-susceptible enterococcal endocarditis: As an alternative to ampicillin 1, 3
- Vertebral osteomyelitis: For penicillin-resistant Enterococcus species 2
Important caveat: Despite 82% of VRE E. faecalis isolates remaining ampicillin-susceptible, daptomycin is frequently overused in clinical practice when ampicillin would be appropriate 4. This represents a significant antimicrobial stewardship opportunity.
Dosing Regimen
Standard Adult Dosing
- 15-20 mg/kg IV every 8-12 hours (actual body weight), not exceeding 2 g per dose 5, 6
- Infuse over at least 60 minutes, at a rate ≤10 mg/min to minimize infusion reactions 6
Serious Infections (Including Endocarditis)
- Loading dose: Consider 25-30 mg/kg IV for critically ill patients 5
- Prolong infusion to 2 hours for loading doses and use antihistamine premedication to prevent red man syndrome 5
Pediatric Dosing
- 15 mg/kg IV every 6 hours for serious infections 5, 7
- Neonates: 15 mg/kg initial dose, then 10 mg/kg every 12 hours (first week of life) or every 8 hours thereafter 6
Therapeutic Drug Monitoring
Target trough concentrations of 10-15 μg/mL are recommended for Enterococcus infections 1, 8. This differs from MRSA infections where 15-20 μg/mL is targeted.
AUC/MIC Targets for Enterococcus
Recent evidence suggests optimal targets vary by species:
- Enterococcus spp: AUC₂₄ 370-540 mg·h/L, Cmin 10-14 mg/L 9
- E. faecium specifically: AUC₂₄ 425-560 mg·h/L, Cmin 10-18 mg/L 9
- AUC₂₄/MIC ≥427 independently predicts treatment success 10
Monitoring Strategy
- Obtain trough levels before the 4th or 5th dose at steady state 5, 8
- Monitor troughs in all patients with serious infections, obesity, renal dysfunction, or fluctuating volumes of distribution 5
- Peak level monitoring is not recommended 5, 8
Combination Therapy Considerations
For enterococcal endocarditis, guidelines recommend:
- With ampicillin/amoxicillin: Add ceftriaxone 2 g every 12 hours OR gentamicin 3 mg/kg/day 1
- With vancomycin: Add gentamicin 3 mg/kg/day 1, 3
- Duration: 4-6 weeks of aminoglycoside for endocarditis; shorter courses acceptable for bacteremia alone 2
Critical warning: Combination vancomycin plus gentamicin increases nephrotoxicity risk and should be avoided when possible 1. For vertebral osteomyelitis, aminoglycosides are optional rather than mandatory 2.
Nephrotoxicity Risk
Nephrotoxicity occurs in approximately 20.8% of patients with Enterococcus infections treated with vancomycin 9. Risk factors include:
- AUC₂₄ >540 mg·h/L independently predicts acute kidney injury 9
- Trough levels >14-15 mg/L increase nephrotoxicity risk 9, 11
- Concomitant nephrotoxins (especially aminoglycosides) 1
Define nephrotoxicity as ≥2-3 consecutive serum creatinine increases of ≥0.5 mg/dL or ≥50% from baseline after several days of therapy 8.
Special Populations
Age Considerations
Patients <40 years are 3.1 times more likely to require every-8-hour dosing rather than every-12-hour dosing 12. Consider empiric dosing of 15 mg/kg IV every 8 hours in younger adults with severe infections and normal renal function.
Renal Impairment
Dose adjustment is mandatory. Initial dose should be ≥15 mg/kg even with mild-moderate renal insufficiency 6. For CrCl <50 mL/min, extend dosing intervals significantly or use nomograms based on creatinine clearance 6.
Clinical Outcomes
Treatment success rates for vancomycin in Enterococcus infections are approximately 72-87% 9, 13. However, solid tumor malignancy and S. aureus co-infection are exploratory risk factors for treatment failure 13.
For urinary tract infections specifically, vancomycin achieves 86.5% success despite only 36.5% of patients reaching target AUC₂₄/MIC 400-600, suggesting serum PK/PD targets may be less critical when the drug concentrates in urine 13.
Key Pitfalls to Avoid
- Using vancomycin first-line: Ampicillin remains superior for susceptible strains, even in VRE E. faecalis (82% ampicillin-susceptible) 4
- Inadequate initial dosing in young patients: Use every-8-hour dosing empirically in patients <40 years 12
- Routine aminoglycoside combination: Only necessary for endocarditis; increases toxicity without clear benefit in other infections 1, 2, 1
- Ignoring species-specific targets: E. faecium may require higher exposure than other Enterococcus species 9
- Treating vancomycin MIC >2 μg/mL isolates: Switch to alternative agents (though rare in Enterococcus) 5